Technology
Health
Pharmaceutical
Zomedica Pharmaceuticals
$0.7229876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.722
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Pre-Market
$0.00 (0.00%) Pre-Market
Why Robinhood?
You can buy or sell ZOM and other stocks, options, ETFs, and crypto commission-free!
About
Zomedica Pharmaceuticals Corp. engages in the discovery, development and commercialization of pharmaceuticals for the companion pet. The company was founded by Gerald L. Read More Solensky, Jr. on January 7, 2013 and is headquartered in Ann Arbor, MI.
Employees
27
Headquarters
Ann Arbor, Michigan
Founded
2013
Market Cap
70.47M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
58.21K
High Today
$0.8272
Low Today
$0.73
Open Price
$0.8272
Volume
6.74K
52 Week High
$2.98
52 Week Low
$0.5918
Collections
Technology
Health
Pharmaceutical
2017 IPO
US
North America
News
MarketBeatMar 5
Stock Price, News, & Analysis for Zomedica Pharmaceuticals
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transder...
Markets InsiderFeb 26
Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results
ANN ARBOR, Mich., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). “We made major strides in 2018 to expand our diagnostic pi...
Price Paid on Robinhood
41% Lower
Right Now
52 Week Low
$0.5918
Average Price Paid
$1.21
52 Week High
$2.98
Earnings
-$0.09
-$0.07
-$0.04
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, Pre-Market